PMV Pharmaceuticals financials
$1.43+5.15%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 |
|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | — |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | — |
| Gross margin | — | — | — | — | — | — |
| Operating income | -$86.2M | -$85.4M | -$80.1M | -$77.0M | -$58.3M | -$34.9M |
| Net income | -$77.7M | -$58.7M | -$69.0M | -$73.3M | -$57.8M | -$34.4M |
| Net margin | — | — | — | — | — | — |
| Diluted EPS | $-1.48 | $-1.14 | $-1.44 | $-1.61 | $-1.28 | $-2.40 |
| EBITDA | -$86.1M | -$84.3M | -$78.9M | -$76.7M | -$58.0M | -$34.6M |
| Operating cash flow | -$73.6M | -$51.3M | -$55.7M | -$63.8M | -$46.6M | -$32.7M |
| Free cash flow | -$73.6M | -$51.9M | -$56.6M | -$71.7M | -$47.9M | -$32.9M |
| Diluted shares | 52.5M | 51.6M | 48.0M | 45.6M | 45.1M | 14.4M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $38.0M | $40.9M | $37.7M | $108.3M | $172.5M | $361.4M |
| Short-term investments | $75.0M | $128.6M | $165.4M | $132.8M | $124.7M | — |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $116.6M | $191.3M | $252.2M | $270.3M | $331.6M | $365.5M |
| Total liabilities | $11.8M | $15.2M | $26.5M | $24.3M | $23.0M | $6.4M |
| Shareholders' equity | $104.7M | $176.1M | $225.7M | $246.0M | $308.6M | $359.1M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology